Development of BCG as a live recombinant vector system: potential use as an HIV vaccine
- PMID: 1845119
Development of BCG as a live recombinant vector system: potential use as an HIV vaccine
Abstract
Bacille Calmette-Guèrin (BCG), a live attenuated tubercle bacillus, is currently the most widely used vaccine in the world. Because of its unique characteristics, including low toxicity, adjuvant potential, and long-lasting immunity, BCG represents a novel vaccine vehicle with which to deliver protective antigens of multiple pathogens. We have developed episomal and integrative expression vectors employing regulatory sequences of major BCG heat shock proteins for stable maintenance and expression of foreign antigens in BCG vaccine strains (22). Shuttle plasmids capable of autonomous replication in Escherichia coli and BCG were constructed with a DNA cassette containing a minimal replicon derived from the Mycobacterium fortuitum plasmid pAL5000. Efficient and stable chromosomal integration of recombinant plasmids into BCG was achieved using a DNA segment containing the mycobacteriophage L5 attachment site and integrase coding sequence. Using the BCG hsp60 and hsp70 stress gene promoters, we were able to express Escherchia coli beta-galactosidase to levels in excess of 10% of total cell protein. The major antigens of HIV-1 gag, pol, and env were also stably expressed using our vector systems. The recombinant BCG elicited long-lasting humoral and cellular immune responses to these antigens in mice. Antibody responses to beta-galactosidase using as few as 200 colony-forming units were detected 6 weeks after immunization, and titers (1:30,000) were sustained for more than 10 weeks. Cellular immune responses, of both cytotoxic T cell (CTL) and helper T lymphocytes, were detected to beta-galactosidase. CTL responses were also induced to the HIV-1 envelope protein. Thus, we have demonstrated stable recombinant antigen expression, processing, and presentation using our recombinant BCG vector system. This live recombinant vector system shows promise as a universally applicable and safe vaccine vehicle for protection against various infectious diseases.
Similar articles
-
New use of BCG for recombinant vaccines.Nature. 1991 Jun 6;351(6326):456-60. doi: 10.1038/351456a0. Nature. 1991. PMID: 1904554
-
Humoral and cell-mediated immune responses to live recombinant BCG-HIV vaccines.Nature. 1991 Jun 6;351(6326):479-82. doi: 10.1038/351479a0. Nature. 1991. PMID: 2046750
-
Enhancement of cell-mediated immune response in mice by whole HIV-1 gag in Mycobacterium bovis BCG as a live vaccine candidate.Southeast Asian J Trop Med Public Health. 2009 Jan;40(1):113-22. Southeast Asian J Trop Med Public Health. 2009. PMID: 19323043
-
[Novel vaccines against M. tuberculosis].Kekkaku. 2006 Dec;81(12):745-51. Kekkaku. 2006. PMID: 17240920 Review. Japanese.
-
Protective immunity elicited by rBCG vaccines.Dev Biol Stand. 1994;82:163-70. Dev Biol Stand. 1994. PMID: 7958471 Review.
Cited by
-
Molecular characterization of heterologous HIV-1gp120 gene expression disruption in mycobacterium bovis BCG host strain: a critical issue for engineering mycobacterial based-vaccine vectors.J Biomed Biotechnol. 2010;2010:357370. doi: 10.1155/2010/357370. Epub 2010 Jun 27. J Biomed Biotechnol. 2010. PMID: 20617151 Free PMC article.
-
Characterization of a novel heat shock protein (Hsp22.5) involved in the pathogenesis of Mycobacterium tuberculosis.J Bacteriol. 2011 Jul;193(14):3497-505. doi: 10.1128/JB.01536-10. Epub 2011 May 20. J Bacteriol. 2011. PMID: 21602349 Free PMC article.
-
Rhesus immune responses to SIV Gag expressed by recombinant BCG vectors are independent from pre-existing mycobacterial immunity.Vaccine. 2015 Oct 13;33(42):5715-5722. doi: 10.1016/j.vaccine.2015.07.010. Epub 2015 Jul 17. Vaccine. 2015. PMID: 26192357 Free PMC article.
-
Recombinant Mycobacterium bovis bacillus Calmette-Guérin secreting merozoite surface protein 1 (MSP1) induces protection against rodent malaria parasite infection depending on MSP1-stimulated interferon gamma and parasite-specific antibodies.J Exp Med. 1998 Sep 7;188(5):845-54. doi: 10.1084/jem.188.5.845. J Exp Med. 1998. PMID: 9730886 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Research Materials
Miscellaneous